Vivos Therapeutics, Inc. VVOS 深 沪
等待开盘 06-26 09:30:00 美东时间
0.4379
-0.003
-0.79%
华盛通- 最 高0.50
- 今 开0.454
- 成交量 14.71万股
- 最 低 0.383
- 昨 收 0.4414
- 总市值 1.01万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 639.05%
- 52周最低 0.383
- 委 比 -52.38%
- 总股本 2.30万
- 历史最高 48.79
- 量 比 0.25
- 振 幅 26.51%
- 历史最低 0.16
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.
04-06 13:33
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics acquires The Sleep Center of Nevada, expanding its OSA diagnostic and treatment capabilities, completing its business model shift, and securing $11M in financing. The deal enhances Vivos' access to high patient volumes and higher-margin revenues.
2025-06-11 12:30
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaini...
2024-09-20 02:57
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index jump...
2024-09-20 00:39
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering.
2024-09-19 22:37
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
U.S. stocks traded higher this morning, with the Nasdaq Composite surging more ...
2024-09-19 21:40
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday.
2024-09-19 11:09
Vivos Therapeutics Secures FDA 510(k) Clearance To Treat Moderate To Severe Pediatric Sleep Apnea And Snoring
Vivos' DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17
2024-09-18 19:02
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.6
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $6.4 to $6.6.
2024-08-20 17:33
